The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Self-citationCrystal Structure of the Tyrosine Phosphatase SHP-2
Hof, P., Pluskey, S., Dhe-Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 985
Tartaglia, M., Kalidas, K., Shaw, A., Song, X., Musat, D. L., van der Burgt, I., Brunner, H. G., Bertola, D. R., Crosby, A., Ion, A., et al. (2002) · The American Journal of Human Genetics · doi:10.1086/340847 · Cited by 802
Self-citationBollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589
Hypertelorism With Turner Phenotype: A New Syndrome With Associated Congenital Heart Disease
Noonan, J. A. (1968) · American Journal of Diseases of Children · doi:10.1001/archpedi.1968.02100020377005 · Cited by 549
Occurrence of myeloproliferative disorder in patients with Noonan syndrome
Bader-Meunier, B., Tchernia, G., Miélot, F., Fontaine, J. L., Thomas, C., Lyonnet, S., Lavergne, J. M., & Dommergues, J. P. (1997) · The Journal of Pediatrics · doi:10.1016/s0022-3476(97)70273-7 · Cited by 177
Juvenile Myelomonocytic Leukemia and Noonan Syndrome
Choong, K. L. M., Freedman, M. H., Chitayat, D. A., Kelly, E., Taylor, G. P., & Zipursky, A. (1999) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199911000-00014 · Cited by 150
Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy
Emanuel, P. D., Shannon, K., & Castleberry, R. P. (1996) · Molecular Medicine Today · doi:10.1016/1357-4310(96)10044-7 · Cited by 75
Spontaneous Remission of Juvenile Chronic Myelomonocytic Leukemia in an Infant with Noonan Syndrome
Fukuda, M., Horibe, K., Miyajima, Y., Matsumoto, K., & Nagashima, M. (1997) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-199703000-00019 · Cited by 42
Cited by
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249
The genetic landscape of high-risk neuroblastoma
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2529 · Cited by 1,186
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
the International Cancer Genome Consortium PedBrain Tumor Project, Jones, D. T. W., Hutter, B., Jäger, N., Korshunov, A., Kool, M., Warnatz, H.-J., Zichner, T., Lambert, S. R., Ryzhova, M., et al. (2013) · Nature Genetics · doi:10.1038/ng.2682 · Cited by 825
Roberts, A. E., Allanson, J. E., Tartaglia, M., & Gelb, B. D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61023-x · Cited by 793
Self-citationOncogenic mechanisms of the Helicobacter pylori CagA protein
Hatakeyama, M. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1433 · Cited by 752
Germline KRAS mutations cause Noonan syndrome
Schubbert, S., Zenker, M., Rowe, S. L., Böll, S., Klein, C., Bollag, G., van der Burgt, I., Musante, L., Kalscheuer, V., Wehner, L.-E., et al. (2006) · Nature Genetics · doi:10.1038/ng1748 · Cited by 730
Self-citationGermline mutations in HRAS proto-oncogene cause Costello syndrome
Aoki, Y., Niihori, T., Kawame, H., Kurosawa, K., Ohashi, H., Tanaka, Y., Filocamo, M., Kato, K., Suzuki, Y., Kure, S., et al. (2005) · Nature Genetics · doi:10.1038/ng1641 · Cited by 679
Protein-tyrosine phosphatases and cancer
Östman, A., Hellberg, C., & Böhmer, F. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1837 · Cited by 657
Ohnishi, N., Yuasa, H., Tanaka, S., Sawa, H., Miura, M., Matsui, A., Higashi, H., Musashi, M., Iwabuchi, K., Suzuki, M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711183105 · Cited by 594
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
Zhang, S., & Zhang, Z.-Y. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.03.011 · Cited by 558
Soranzo, N., Spector, T. D., Mangino, M., Kühnel, B., Rendon, A., Teumer, A., Willenborg, C., Wright, B., Chen, L., Li, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.467 · Cited by 523
Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers
Wang, Z., Shen, D., Parsons, D. W., Bardelli, A., Sager, J., Szabo, S., Ptak, J., Silliman, N., Peters, B. A., van der Heijden, M. S., et al. (2004) · Science · doi:10.1126/science.1096096 · Cited by 522
Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Helicobacter pylori CagA targets PAR1/MARK kinase to disrupt epithelial cell polarity
Saadat, I., Higashi, H., Obuse, C., Umeda, M., Murata-Kamiya, N., Saito, Y., Lu, H., Ohnishi, N., Azuma, T., Suzuki, A., et al. (2007) · Nature · doi:10.1038/nature05765 · Cited by 501
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Shp2 Regulates Src Family Kinase Activity and Ras/Erk Activation by Controlling Csk Recruitment
Zhang, S. Q., Yang, W., Kontaridis, M. I., Bivona, T. G., Wen, G., Araki, T., Luo, J., Thompson, J. A., Schraven, B. L., Philips, M. R., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00050-4 · Cited by 447
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis
Loh, M. L. (2004) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 427
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
Cordeddu, V., Di Schiavi, E., Pennacchio, L. A., Ma'ayan, A., Sarkozy, A., Fodale, V., Cecchetti, S., Cardinale, A., Martin, J., Schackwitz, W., et al. (2009) · Nature Genetics · doi:10.1038/ng.425 · Cited by 419
Self-citationDiversity and functional consequences of germline and somatic PTPN11 mutations in human disease
Tartaglia, M., Martinelli, S., Stella, L., Bocchinfuso, G., Flex, E., Cordeddu, V., Zampino, G., van der Burgt, I., Palleschi, A., Petrucci, T. C., et al. (2006) · The American Journal of Human Genetics · doi:10.1086/499925 · Cited by 415
Self-citationNoonan syndrome and clinically related disorders
Tartaglia, M., Gelb, B. D., & Zenker, M. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.09.002 · Cited by 414
Self-citationThe tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.641 · Cited by 374
Self-citationPTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders
Aoki, Y., Niihori, T., Narumi, Y., Kure, S., & Matsubara, Y. (2008) · Human Mutation · doi:10.1002/humu.20748 · Cited by 365
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Self-citationMultiple loci influence erythrocyte phenotypes in the CHARGE Consortium
Ganesh, S. K., Zakai, N. A., van Rooij, F. J. A., Soranzo, N., Smith, A. V., Nalls, M. A., Chen, M.-H., Kottgen, A., Glazer, N. L., Dehghan, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.466 · Cited by 358
NOONAN SYNDROME AND RELATED DISORDERS: Genetics and Pathogenesis
Tartaglia, M., & Gelb, B. D. (2005) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.6.080604.162305 · Cited by 355
Self-citationGenetics of Myeloid Malignancies: Pathogenetic and Clinical Implications
Fröhling, S., Scholl, C., Gilliland, D. G., & Levine, R. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.010 · Cited by 353
Hornbeck, P. V., Kornhauser, J. M., Latham, V., Murray, B., Nandhikonda, V., Nord, A., Skrzypek, E., Wheeler, T., Zhang, B., & Gnad, F. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1159 · Cited by 346
PTPN11 (Shp2) Mutations in LEOPARD Syndrome Have Dominant Negative, Not Activating, Effects
Kontaridis, M. I., Swanson, K. D., David, F. S., Barford, D., & Neel, B. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513068200 · Cited by 338
Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis
Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332
Chou, W.-C., Chou, S.-C., Liu, C.-Y., Chen, C.-Y., Hou, H.-A., Kuo, Y.-Y., Lee, M.-C., Ko, B.-S., Tang, J.-L., Yao, M., et al. (2011) · Blood · doi:10.1182/blood-2011-02-339747 · Cited by 322
Protein tyrosine phosphatases in the JAK/STAT pathway
Xu, D. (2008) · Frontiers in Bioscience · doi:10.2741/3051 · Cited by 307
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
Agazie, Y. M., & Hayman, M. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7875-7886.2003 · Cited by 306
Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options
de Lange, J., van den Akker, H. P., & van den Berg, H. (2007) · Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology · doi:10.1016/j.tripleo.2007.04.003 · Cited by 304
Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303
“…and KRAS gene lesions have diverse abilities to perturb signaling traffic [Chan et al., 2005; Mohi et al., 2005; Schubbert et al., 2005, 2006, 2007a; Seeburg et al., 1984; Tartaglia et al., 2003, 2006], suggesting that cancer-associated lesions might severely affect embryonic or fetal development.”
BackgroundSelf-citationAndersen, J. N., Jansen, P. G., Echwald, S. M., Mortensen, O. H., Fukada, T., Del Vecchio, R., Tonks, N. K., & M⊘ller, N. P. H. (2004) · The FASEB Journal · doi:10.1096/fj.02-1212rev · Cited by 303
The genomic landscape of juvenile myelomonocytic leukemia
Stieglitz, E., Taylor-Weiner, A. N., Chang, T. Y., Gelston, L. C., Wang, Y.-D., Mazor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S. R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3400 · Cited by 301
Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307203101 · Cited by 299
Takahashi-Kanemitsu, A., Knight, C. T., & Hatakeyama, M. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0339-5 · Cited by 299
Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298
Diverse Biochemical Properties of Shp2 Mutants
Keilhack, H., David, F. S., McGregor, M., Cantley, L. C., & Neel, B. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504699200 · Cited by 298
Liu, B. A., Jablonowski, K., Raina, M., Arcé, M., Pawson, T., & Nash, P. D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.001 · Cited by 294
Helicobacter pylori and gastric carcinogenesis
Hatakeyama, M. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0014-1 · Cited by 291
The natural history of Noonan syndrome: a long-term follow-up study
Shaw, A. C., Kalidas, K., Crosby, A. H., Jeffery, S., & Patton, M. A. (2006) · Archives of Disease in Childhood · doi:10.1136/adc.2006.104547 · Cited by 291
Tartaglia, M. (2004) · Blood · doi:10.1182/blood-2003-11-3876 · Cited by 289
Self-citationRipperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
Self-citationDiscovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor
Chen, L., Sung, S.-S., Yip, M. L. R., Lawrence, H. R., Ren, Y., Guida, W. C., Sebti, S. M., Lawrence, N. J., & Wu, J. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025536 · Cited by 279
The Tyrosine Phosphatase Shp2 in Development and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
The role of Shp2 (PTPN11) in cancer
Mohi, M. G., & Neel, B. G. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.011 · Cited by 274
The Molecular Basis of Leukemia
Gilliland, D. G., Jordan, C. T., & Felix, C. A. (2004) · Hematology · doi:10.1182/asheducation-2004.1.80 · Cited by 273
The cardiofaciocutaneous syndrome
Roberts, A., Allanson, J., Jadico, S. K., Kavamura, M. I., Noonan, J., Opitz, J. M., Young, T., & Neri, G. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.042796 · Cited by 271
Kratz, C. P. (2005) · Blood · doi:10.1182/blood-2005-02-0531 · Cited by 267
Protein Tyrosine Phosphatases as Drug Targets: Strategies and Challenges of Inhibitor Development
Barr, A. J. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.241 · Cited by 266
HATAKEYAMA, M. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.013 · Cited by 261
Molecular mechanism of SHP2 activation by PD-1 stimulation
Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H. J., Kirkpatrick, J., Rios, P., Schamel, W. W., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 262
Aceto, N., Sausgruber, N., Brinkhaus, H., Gaidatzis, D., Martiny-Baron, G., Mazzarol, G., Confalonieri, S., Quarto, M., Hu, G., Balwierz, P. J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2645 · Cited by 261
Martinelli, S., De Luca, A., Stellacci, E., Rossi, C., Checquolo, S., Lepri, F., Caputo, V., Silvano, M., Buscherini, F., Consoli, F., et al. (2010) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2010.06.015 · Cited by 259
“the discovery of PTPN11’s involvement in leukemogenesis.(20,21) Here, we provide evidence that germline mutations in the Cas-Br-M (murine) ecotropic retroviral transforming sequence (CBL [MIM 165360]) gene, which encodes a multivalent adaptor protein with an established role in myeloid malignancies, can underlie a cli…”
BackgroundSelf-citationKortüm, K. M., Mai, E. K., Hanafiah, N. H., Shi, C.-X., Zhu, Y.-X., Bruins, L., Barrio, S., Jedlowski, P., Merz, M., Xu, J., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698092 · Cited by 255
Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis
Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M. (2015) · Nature Communications · doi:10.1038/ncomms9859 · Cited by 249
Protein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
SHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231
Calcium signaling in vertebrate embryonic patterning and morphogenesis
Slusarski, D. C., & Pelegri, F. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2007.04.043 · Cited by 178
“This syndrome is thought to be caused by mutations in a src homology 2-containing protein tyrosine phosphatase (SHP-2/ PTPN11), which cause its constitutive activation (Tartaglia et al., 2001, 2003; Araki et al., 2004).”
BackgroundDiscovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172
PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
LaRochelle, J. R., Fodor, M., Vemulapalli, V., Mohseni, M., Wang, P., Stams, T., LaMarche, M. J., Chopra, R., Acker, M. G., & Blacklow, S. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06823-9 · Cited by 167
The Phosphatase SHP2 Regulates the Spacing Effect for Long-Term Memory Induction
Pagani, M. R., Oishi, K., Gelb, B. D., & Zhong, Y. (2009) · Cell · doi:10.1016/j.cell.2009.08.033 · Cited by 157
“Gain-of-function (GOF)germlinePTPN11mutations causeabout 50% of NS cases (Tartaglia et al., 2001) and somatic mutations with generally stronger GOF effects cause certain childhood leukemias ( Tartaglia et al., 2003 ).”
Self-citationChan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R. (2005) · Blood · doi:10.1182/blood-2004-10-4002 · Cited by 156
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06814-w · Cited by 133
Predisposition to cancer in children and adolescents
Kratz, C. P., Jongmans, M. C., Cavé, H., Wimmer, K., Behjati, S., Guerrini-Rousseau, L., Milde, T., Pajtler, K. W., Golmard, L., Gauthier-Villars, M., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(20)30275-3 · Cited by 129
Song, Y., Zhao, M., Zhang, H., & Yu, B. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107966 · Cited by 125
A comprehensive review of SHP2 and its role in cancer
Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119
He, M., Xu, M., Zhang, B., Liang, J., Chen, P., Lee, J.-Y., Johnson, T. A., Li, H., Yang, X., Dai, J., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu583 · Cited by 106
“1) was previously associated with Noonan syndrome (19), a Mendelian disorder characterized by proportionately short stature and other symptoms such as dysmorphic facial features, heart disease (20) and acute myeloid leukemia (21).”
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors
Sarver, P., Acker, M., Bagdanoff, J. T., Chen, Z., Chen, Y.-N., Chan, H., Firestone, B., Fodor, M., Fortanet, J., Hao, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01726 · Cited by 87
Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations
Yu, Z.-H., Zhang, R.-Y., Walls, C. D., Chen, L., Zhang, S., Wu, L., Liu, S., & Zhang, Z.-Y. (2014) · Biochemistry · doi:10.1021/bi5002695 · Cited by 87
Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations
Oishi, K., Gaengel, K., Krishnamoorthy, S., Kamiya, K., Kim, I.-K., Ying, H., Weber, U., Perkins, L. A., Tartaglia, M., Mlodzik, M., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddi471 · Cited by 81
Self-citationDiscovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders
Yang, X., Wang, Z., Pei, Y., Song, N., Xu, L., Feng, B., Wang, H., Luo, X., Hu, X., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113341 · Cited by 85
Targeting Ras in myeloid leukemias
Braun, B. S., & Shannon, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1005 · Cited by 74
Structure and function of Gab2 and its role in cancer (Review)
DING, C.-B., YU, W.-N., FENG, J.-H., & LUO, J.-M. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3951 · Cited by 71
LaRochelle, J. R., Fodor, M., Xu, X., Durzynska, I., Fan, L., Stams, T., Chan, H. M., LaMarche, M. J., Chopra, R., Wang, P., et al. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01287 · Cited by 70
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Off‐target inhibition by active site‐targeting SHP 2 inhibitors
Tsutsumi, R., Ran, H., & Neel, B. G. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12493 · Cited by 54
Targeted Degradation of the Oncogenic Phosphatase SHP2
Vemulapalli, V., Donovan, K. A., Seegar, T. C. M., Rogers, J. M., Bae, M., Lumpkin, R. J., Cao, R., Henke, M. T., Ray, S. S., Fischer, E. S., et al. (2021) · Biochemistry · doi:10.1021/acs.biochem.1c00377 · Cited by 43
Huang, W., Saberwal, G., Horvath, E., Zhu, C., Lindsey, S., & Eklund, E. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00036-06 · Cited by 41
New structural and functional insight into the regulation of Ras
Kano, Y., Cook, J. D., Lee, J. E., & Ohh, M. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.06.006 · Cited by 38
Tang, K., Zhao, M., Wu, Y.-H., Wu, Q., Wang, S., Dong, Y., Yu, B., Song, Y., & Liu, H.-M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114106 · Cited by 20
A hotspot phosphorylation site on SHP2 drives oncoprotein activation and drug resistance
Karunaraj, P., Scheele, R., Wells, M. L., Rathod, R., Gokulu, I. S., Abrahamson, S. R., Taylor, L., Chowdhury, L., Kazmi, A., Song, W., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70060-8 · Cited by 7
Metadata
- Authors
- Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D.
- Venue
- Nature Genetics
- Published
- 2003-04-28
- Volume
- 34
- Issue
- 2
- Pages
- 148-150
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2082448876
- Cited by
- 1,033
- References
- 9
- FWCI
- 20.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.